Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2018

Open Access 01-12-2018 | Research article

Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials

Authors: Mingmin Shi, Lei Chen, Haobo Wu, Yangxin Wang, Wei Wang, Yujie Zhang, Shigui Yan

Published in: BMC Musculoskeletal Disorders | Issue 1/2018

Login to get access

Abstract

Background

Aseptic loosening and osteolysis are the most common indications after TKA for revision surgery. This meta-analysis which included high-quality randomized controlled trials (RCTs) aimed to analyze the effect of bisphosphonates (BPs) on maintaining periprosthetic bone mineral density (BMD) after total knee arthroplasty.

Methods

PubMed, AMED, EMBASE, the Cochrane library, ISI Web of Science, and China National Knowledge Infrastructure were systematically searched, five RCTs were included and the total number of participants was 188. The weighted mean differences with 95% confidence interval were calculated to evaluate the efficacy of BPs on total BMD of knee and the BMD of different periprosthetic regions. A descriptive review was performed for BP-related adverse effects.

Results

The BPs group presented significantly higher total BMD in proximal part of the tibia than the control group at 3 and 6 months (P < 0.05), but no significant difference at 12 months (P = 0.09). The BPs group presented significantly higher BMD in the distal aspect of the femur than that in the control group at 3, 6, 12 months. The BPs group presented significantly higher periprosthetic BMD than that in the control group at 3, 6 and 12 months in tibial medial and lateral metaphyseal region, and femoral anterior, central and posterior metaphyseal region (p < 0.05), but no significant difference for tibial diaphyseal region at 3, 6, and 12 months. None of the included studies described severe or fatal adverse effects related to BPs.

Conclusion

BPs have a short-term effect on reducing periprosthetic bone loss after total knee arthroplasty. Compared with diaphyseal region, BPs are more effective on the preservation of BMD in medial lateral metaphyseal regions of proximal tibia and in anterior, central, and posterior metaphyseal region of distal femur.
Literature
1.
Huang CC, Jiang CC, Hsieh CH, Tsai CJ, Chiang H. Local bone quality affects the outcome of prosthetic total knee arthroplasty. J Orthop Res. 2016;34(2):240–8.CrossRefPubMed
2.
Winther N, Jensen C, Petersen M, Lind T, Schrøder H, Petersen M. Changes in bone mineral density of the proximal tibia after uncemented total knee arthroplasty. A prospective randomized study. Int Orthop. 2016;40(2):285–94.CrossRefPubMed
3.
van Loon CJ, Oyen WJ, de Waal Malefijt MC, Verdonschot N. Distal femoral bone mineral density after total knee arthroplasty: a comparison with general bone mineral density. Arch Orthop Trauma Surg. 2001;121(5):282–5.CrossRefPubMed
4.
Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, Gretzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop. 2006;77(2):177–97.CrossRefPubMed
5.
Munro JT, Pandit S, Walker CG, Clatworthy M, Pitto RP. Loss of tibial bone density in patients with rotating- or fixed-platform TKA. Clin Orthop Relat Res. 2010;468(3):775–81.CrossRefPubMed
6.
Järvenpää J, Soininvaara T, Kettunen J, Miettinen H, Kröger H. Changes in bone mineral density of the distal femur after total knee arthroplasty: a 7-year DEXA follow-up comparing results between obese and nonobese patients. Knee. 2014;21(1):232–5.CrossRefPubMed
7.
Spinarelli A, Petrera M, Vicenti G, Pesce V, Patella V. Total knee arthroplasty in elderly osteoporotic patients. Aging Clin Exp Res. 2011;23(2 Suppl):78–80.PubMed
8.
Petersen MM, Lauritzen JB, Pedersen JG, Lund B. Decreased bone density of the distal femur after uncemented knee arthroplasty. A 1-year follow-up of 29 knees. Acta Orthop Scand. 1996;67(4):339–44.CrossRefPubMed
9.
Seki T, Omori G, Koga Y, Suzuki Y, Ishii Y, Takahashi HE. Is bone density in the distal femur affected by use of cement and by femoral component design in total knee arthroplasty? J Orthop Sci. 1999;4(3):180–6.CrossRefPubMed
10.
Soininvaara TA, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM, Kröger HP. Periprosthetic femoral bone loss after total knee arthroplasty: 1-year follow-up study of 69 patients. Knee. 2004;11(4):297–302.CrossRefPubMed
11.
Cherian JJ, Jauregui JJ, Banerjee S, Pierce T, Mont MA. What host factors affect aseptic loosening after THA and TKA? Clin Orthop Relat Res. 2015;473(8):2700–9.CrossRefPubMedPubMedCentral
12.
Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23(4):508–16.CrossRefPubMed
13.
Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther. 2003;5(1):12–24.CrossRefPubMed
14.
Fu SH, Wang CY, Yang RS, Wu FL, Hsiao FY. Bisphosphonate use and the risk of undergoing Total knee arthroplasty in osteoporotic patients with osteoarthritis: a Nationwide cohort study in Taiwan. J Bone Joint Surg Am. 2017;99(11):938–46.CrossRefPubMed
15.
Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS. Association of Bisphosphonate use and Risk of revision after THA: outcomes from a US Total joint replacement registry. Clin Orthop Relat Res. 2015;473(11):3412–20.CrossRefPubMedPubMedCentral
16.
Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kröger PJ. Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int. 2002;71(6):472–7.CrossRefPubMed
17.
Han H, Li X, Wang Y, Zeng X, Preventing XC. Prosthesis loose after joint replacement. Chinese journal of surgery of integrated traditional and western. Medicine. 2003;9(3):179–82.
18.
Wang CJ, Wang JW, Ko JY, Weng LH, Huang CC. Three-year changes in bone mineral density around the knee after a six-month course of oral alendronate following total knee arthroplasty. A prospective, randomized study J Bone Joint Surg Am. 2006;88(2):267–72.CrossRefPubMed
19.
Abu-Rajab RB, Watson W, Gallacher P, Walker B, Meek RMD. The effect of 6 months oral alendronate treatment on periprosthetic bone loss after total knee arthroplasty. Eur J Orthop Surg Traumatol. 2009;19:231–5.CrossRef
20.
Jaroma AV, Soininvaara TA, Kröger H. Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. Bone Joint J. 2015;97-B(3):337–45.CrossRefPubMed
21.
Lin T, Yan SG, Cai XZ, Ying ZM. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2012;23(6):1823–34.CrossRefPubMed
22.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.CrossRefPubMed
23.
JPT H, Green S. Cochrane handbook for systematic reviews of interventions. Chichester, England: Wiley-Blackwell; 2008.
24.
25.
Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Chen HS. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A(11):2121–6.CrossRefPubMed
26.
Lee JK, Lee CH, Choi CH. QCT bone mineral density responses to 1 year of oral bisphosphonate ate after total knee replacement for knee osteoarthritis. Osteoporos Int. 2013;24(1):287–92.CrossRefPubMed
27.
Hansson U, Toksvig-Larsen S, Ryd L, Aspenberg P. Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: a double-blind randomized RSA study. Acta Orthop. 2009;80(1):41–5.CrossRefPubMedPubMedCentral
28.
Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011;343:d7222.CrossRefPubMedPubMedCentral
29.
Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40(4):275–84. e1–2CrossRefPubMed
30.
Ji WP, Wang XL, Ma MQ, Lan J, Li H. Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss. Eur J Orthop Surg Traumatol. 2013;23(5):565–71.CrossRefPubMed
31.
Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, de Vries F, et al. Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum. 2011;63(4):992–1001.CrossRefPubMed
32.
Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, et al. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol. 2014;66(11):3233–40.CrossRefPubMed
33.
Lee JK, Choi CH, Kang CN. Quantitative computed tomography assessment of bone mineral density after 2 years' oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty. J Int Med Res. 2013;41(3):878–88.CrossRefPubMed
34.
Jaroma A, Soininvaara T, Kröger H. Periprosthetic tibial bone mineral density changes after total knee arthroplasty. Acta Orthop. 2016;87(3):268–73.CrossRefPubMedPubMedCentral
35.
Srinivasan P, Miller MA, Verdonschot N, Mann KA, Janssen D. Experimental and computational micromechanics at the tibial cement-trabeculae interface. J Biomech. 2016;49(9):1641–8.CrossRefPubMedPubMedCentral
36.
Namba RS, Inacio MC, Cheetham TC, Dell RM, Paxton EW, Khatod MX. Lower Total knee arthroplasty revision risk associated with bisphosphonate use, even in patients with normal bone density. J Arthroplast. 2016;31(2):537–41.CrossRef
Metadata
Title
Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials
Authors
Mingmin Shi
Lei Chen
Haobo Wu
Yangxin Wang
Wei Wang
Yujie Zhang
Shigui Yan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2018
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-018-2101-z

Other articles of this Issue 1/2018

BMC Musculoskeletal Disorders 1/2018 Go to the issue

Research article

Physical activity status by pain severity in patients with knee osteoarthritis: a nationwide study in Korea

Research article

Deep vein thrombosis following the treatment of lower limb pathologic bone fractures – a comparative study

Research article

Use of The Global Alliance for Musculoskeletal Health survey module for estimating the population prevalence of musculoskeletal pain: findings from the Solomon Islands

Research article

A new acute scaphoid fracture assessment method: a reliability study of the ‘long axis’ measurement

Research article

Anterior cruciate ligament reconstruction with quadriceps tendon-patellar bone allograft: matched case control study

Research article

Quantitative analysis of near-implant magnesium accumulation for a Si-containing coated AZ31 cage from a goat cervical spine fusion model